Apoptosis

, Volume 10, Issue 4, pp 743–758

Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis

  • H. C. A. Drexler
  • M. Euler
Article

Proteasome inhibitors are able to efficiently induce apoptosis in many tumor cells while leaving quiescent, untransformed cells largely unharmed. Here we investigated the further enhancement of proteasome inhibitor-mediated apoptosis induction in Bcr-Abl positive K562 CML cells by simultaneous treatment with different histone deacetylase inhibitors (HDIs). Combining proteasome and HDIs resulted in rapid hyperacetylation of histone H3 and accumulation of polyubiquitinated proteins and the synergistic induction of apoptosis. Apoptosis induction was associated with caspase 8, 3 and 9 activation, Bid processing, destruction of the mitochondrial membrane potential, cleavage of PARP and lamin B and extensive DNA fragmentation. The pan-caspase inhibitor Z-VAD-FMK and the caspase-8 inhibitor Z-IETD-FMK could inhibit K562 cell apoptosis. Apoptosis was also delayed by overexpression of Bcl-xL, as well as by crmA, a known inhibitor of caspases 1 and 8. Caspase 8 activity could still be detected in the presence of ectopic Bcl-xL, but not in crmA transfected cells. The most striking anti-apoptotic effect though was obtained by the translational inhibitor cycloheximide, which abolished caspase 8 processing, blocked Bid cleavage and maintained the mitochondrial transmembrane potential. Apoptosis by the combination treatment occurred independently from CD95/Fas receptor stimulation. These results demonstrated that transcriptional activation by HDIs combined with proteasome inhibitor mediated posttranslational stabilization of protein(s) results in significantly enhanced CML apoptosis which was striktly dependent on uninterrupted protein synthesis.

Keywords

apoptosis Bcr-Abl chemoresistance histone deacetylase inhibitor leukemia proteasome 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82(2): 373–428.PubMedGoogle Scholar
  2. 2.
    Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 2002; 14(6): 628–634.CrossRefPubMedGoogle Scholar
  3. 3.
    Almond JB, Cohen GM. The proteasome: A novel target for cancer chemotherapy. Leukemia 2002; 16(4): 433–443.CrossRefPubMedGoogle Scholar
  4. 4.
    Drexler HC, Pebler S. Inducible p27(Kip1) expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors. Cell Death Differ 2003; 10(3): 290–301.CrossRefPubMedGoogle Scholar
  5. 5.
    An B, Goldfarb RH, Siman R, Dou Q. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998; 5(12): 1062–1075.CrossRefPubMedGoogle Scholar
  6. 6.
    Richardson G, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348(26): 2609–2617.PubMedGoogle Scholar
  7. 7.
    Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8(8): 2505–2511.PubMedGoogle Scholar
  8. 8.
    Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol, 2002; 20(22): 4420–4427.CrossRefPubMedGoogle Scholar
  9. 9.
    Herrmann JL, Briones Jr. F, Brisbay S, Logothetis CJ, McDonnell TJ. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 1998; 17(22): 2889–2899.CrossRefPubMedGoogle Scholar
  10. 10.
    Drexler HCA. Activation of the cell death program by inhibition of proteasome function. Proc Nat Acad Sci USA 1997; 94(3): 855–860.CrossRefPubMedGoogle Scholar
  11. 11.
    Chandra J, Niemer I, Gilbreath J, et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood, 1998; 92(11): 4220–4229.PubMedGoogle Scholar
  12. 12.
    Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to Tnf-alpha-initiated apoptosis. Brit J Cancer, 1998; 77(7): 1103–1107.PubMedGoogle Scholar
  13. 13.
    Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 2000; 60(9): 2429–2434.PubMedGoogle Scholar
  14. 14.
    Bedi A, Barber JP, Bedi GC, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 1995; 86(3): 1148–1158.PubMedGoogle Scholar
  15. 15.
    McGahon A, Bissonnette R, Schmitt M. et al. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83(5): 1179–1187.PubMedGoogle Scholar
  16. 16.
    Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem 2000; 275(50): 39223–39230.CrossRefPubMedGoogle Scholar
  17. 17.
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344(14): 1038–1042.CrossRefPubMedGoogle Scholar
  18. 18.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1031–1037.CrossRefPubMedGoogle Scholar
  19. 19.
    Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 2002; 100(6): 1965–1971.CrossRefPubMedGoogle Scholar
  20. 20.
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293(5531): 876–880.CrossRefPubMedGoogle Scholar
  21. 21.
    le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood, 2000; 95(5): 1758–1766.PubMedGoogle Scholar
  22. 22.
    Weisberg E, Griffin JD, Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood, 2000; 95(11): 3498–3505.PubMedGoogle Scholar
  23. 23.
    Dou QP, McGuire TF, Peng Y, An B. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther 1999; 289(2): 781–790.PubMedGoogle Scholar
  24. 24.
    Naujokat C, Sezer O, Zinke H, et al. Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 2000; 65(4): 221–236.CrossRefPubMedGoogle Scholar
  25. 25.
    Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998; 20(8): 615–626.CrossRefPubMedGoogle Scholar
  26. 26.
    He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 1998; 18(2): 126–135.CrossRefPubMedGoogle Scholar
  27. 27.
    Lin RJ, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391(6669): 811–814.CrossRefPubMedGoogle Scholar
  28. 28.
    Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391(6669): 815–818.CrossRefPubMedGoogle Scholar
  29. 29.
    Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1(4): 287–299.CrossRefPubMedGoogle Scholar
  30. 30.
    Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92(15): 1210–1216.CrossRefPubMedGoogle Scholar
  31. 31.
    Bernhard D, Skvortsov S, Tinhofer I, et al. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ 2001; 8(10): 1014–1021.CrossRefPubMedGoogle Scholar
  32. 32.
    Klisovic MI, Maghraby EA, Parthun MR, et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 2003; 17(2): 350–358.CrossRefPubMedGoogle Scholar
  33. 33.
    Kurz EU, Wilson SE, Leader KB, et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 2001; 1(2): 121–131.PubMedGoogle Scholar
  34. 34.
    Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K, Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003; 101(8): 3236–3239.CrossRefPubMedGoogle Scholar
  35. 35.
    Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci USA 2004; 101(2): 540–545.CrossRefPubMedGoogle Scholar
  36. 36.
    Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991; 139(2): 271–279.CrossRefGoogle Scholar
  37. 37.
    Yin L, Laevsky G, Giardina C, Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 2001; 276(48): 44641–44646.CrossRefPubMedGoogle Scholar
  38. 38.
    Hitomi J, Katayama T, Eguchi Y, et al. Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. J Cell Biol 2004; 165(3): 347–356.CrossRefPubMedGoogle Scholar
  39. 39.
    Saleh M, Vaillancourt JP, Graham RK, et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004; 429(6987): 75–79.CrossRefPubMedGoogle Scholar
  40. 40.
    Glick RD, Swendeman SL, Coffey DC, et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 1999; 59(17): 4392–4399.PubMedGoogle Scholar
  41. 41.
    Kwon SH, Ahn SH, Kim YK, et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2002; 277(3): 2073–2080.CrossRefPubMedGoogle Scholar
  42. 42.
    Vrana JA, Grant S. Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade. Blood, 2001; 97(7): 2105–2114.CrossRefPubMedGoogle Scholar
  43. 43.
    Chen WJ, Lin JK. Induction of G1 arrest and apoptosis in human Jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27Kip1, p21Cip1/WAF1 and Bax proteins. J Biol Chem 2004.Google Scholar
  44. 44.
    Di Bacco AM, Cotter TG. p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases. Br J Haematol 2002; 117(3): 588–597.CrossRefPubMedGoogle Scholar
  45. 45.
    Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003; 63(16): 5126–5135.PubMedGoogle Scholar
  46. 46.
    Garcia-Calvo M, Peterson EP, Leiting B, et al. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998; 273(49): 32608–32613.CrossRefPubMedGoogle Scholar
  47. 47.
    McGahon AJ, Nishioka WK, Martin SJ, et al. Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem, 1995; 270(38): 22625–22631.CrossRefPubMedGoogle Scholar
  48. 48.
    Kim K. Proteasome inhibitors sensitize human vascular smooth muscle cells to Fas (CD95)-mediated death. Biochem Biophys Res Commun 2001; 281(2): 305–310.CrossRefPubMedGoogle Scholar
  49. 49.
    Tani E, Kitagawa H, Ikemoto H, Matsumoto T. Proteasome inhibitors induce Fas-mediated apoptosis by c-Myc accumulation and subsequent induction of FasL message in human glioma cells. FEBS Lett 2001; 504(1–2): 53–58.CrossRefPubMedGoogle Scholar
  50. 50.
    Giuliano M, Lauricella M, Calvaruso G, et al. The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res 1999; 59(21): 5586–5595.PubMedGoogle Scholar
  51. 51.
    Yu C, Rahmani M, Conrad D, et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood, 2003; 102(10): 3765–3774.CrossRefPubMedGoogle Scholar
  52. 52.
    Tan S, Seow TK, Liang RC, et al. Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int J Cancer, 2002; 98(4): 523–531.CrossRefPubMedGoogle Scholar
  53. 53.
    Faucheu C, Diu A, Chan AW, et al. A novel human protease similar to the interleukin-1 beta converting enzyme induces apoptosis in transfected cells. Embo J, 1995; 14(9): 1914–1922.PubMedGoogle Scholar
  54. 54.
    Luciano F, Jacquel A, Colosetti P, et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22(43): 6785–6793.CrossRefPubMedGoogle Scholar
  55. 55.
    Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003; 278(21): 18811–18816.CrossRefGoogle Scholar
  56. 56.
    Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101(4): 1530–1534.CrossRefPubMedGoogle Scholar
  57. 57.
    Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene, 2003; 22(46): 7108–7122.CrossRefPubMedGoogle Scholar
  58. 58.
    Chauhan D, Li G, Podar K, et al. Bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 2003; 103(8): 3158–3166.CrossRefPubMedGoogle Scholar
  59. 59.
    Bogner C, Ringshausen I, Schneller F, et al. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells. Br J Haematol, 2003; 122(2): 260–268.CrossRefPubMedGoogle Scholar
  60. 60.
    Chen L, Smith L, Wang Z, Smith JB. Preservation of caspase-3 subunits from degradation contributes to apoptosis evoked by lactacystin: Any single lysine or lysine pair of the small subunit is sufficient for ubiquitination. Mol Pharmacol, 2003; 64(2): 334–345.CrossRefPubMedGoogle Scholar
  61. 61.
    Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003; 2(12): 1273–1284.PubMedGoogle Scholar
  62. 62.
    Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 2003; 66(8): 1537–1545.CrossRefPubMedGoogle Scholar
  63. 63.
    Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002; 16(7): 1331–1343.CrossRefPubMedGoogle Scholar
  64. 64.
    Rahmani M, Dai Y, Grant S. The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process. Exp Cell Res 2002; 277(1): 31–47.CrossRefPubMedGoogle Scholar
  65. 65.
    Maecker HL, Koumenis C, Giaccia AJ. p53 promotes selection for Fas-mediated apoptotic resistance. Cancer Res 2000; 60(16): 4638–4644.PubMedGoogle Scholar
  66. 66.
    Maecker HL, Yun Z, Maecker HT, Giaccia AJ. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002; 2(2): 139–148.CrossRefPubMedGoogle Scholar
  67. 67.
    Travers KJ, Patil CK, Wodicka L, et al. Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. Cell 2000; 101(3): 249–258.PubMedGoogle Scholar
  68. 68.
    Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002; 110(10): 1389–1398.CrossRefPubMedGoogle Scholar
  69. 69.
    Haynes CM, Titus EA, Cooper AA. Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol Cell 2004; 15(5): 767–776.CrossRefPubMedGoogle Scholar
  70. 70.
    Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004; 24(22): 9695–9704.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • H. C. A. Drexler
    • 1
    • 2
  • M. Euler
    • 1
  1. 1.Max Planck Institut für physiologische und klinische ForschungBad NauheimGermany
  2. 2.Universität Würzburg Institut für medizinische Strahlenkunde und Zellforschung-MSZWürzburgGermany

Personalised recommendations